Pfizer to buy back NY plant for sale or closure; Italian pharma nabs Frik Ilac for $130M;

  @FiercePharma: Study: Pfizer's Chantix raises heart risks 72%. Story | Follow @FiercePharma

> Pfizer has decided to buy back a manufacturing facility in Rouses Point, NY, from current owner Akrimax Pharmaceuticals, and now says it plans to either sell or shutter it by 2013. Article

> Italy's Recordati has hit the acquisition trail in Turkey again and is buying Frik Ilac, one of the fastest-growing pharmaceutical companies in the country, for about $130 million. Item

> A U.K. judge denied Eli Lilly's bid to dismiss a Zyprexa patent challenge from Neopharm. However, the judge tossed one of Neopharm's claims and ordered the company to post bond to cover Lilly's legal fees if it loses the case. Report

> The Indian government has deferred until October the implementation of barcode technology for tracing and tracking export consignments of pharmaceuticals. News

> A new generation of powerful breath tests detect diseases. Item

> Bacteria on raw poultry meat in the Netherlands may be a source of superbugs in people, according to a study that suggests the use of antibiotics in food animals is causing life-saving drugs to lose their potency. Article

> Researchers want better way to diagnose asthma. Report

> Private equity group TPG Capital will take diagnostics firm Immucor private in a near $2 billion deal that could give the company's niche blood-testing products a more global profile. Article

> Biomarkers in feces could replace colonoscopies. News 

> India's Lupin said it has received FDA approval to market its version of the Novartis high blood pressure treatment Lotrel. Report

Biotech News

@FierceBiotech: J&J gets FDA green light for blockbuster blood thinner Xarelto. News | Follow @FierceBiotech

@JohnCFierce: Totting up the $$ in Rib-X antibacterial pact with Sanofi: $10M upfront, $9M for research and $186M in milestones per. Item | Follow @JohnCFierce

> Sanofi teams with Rib-X on new crop of antibiotics. Piece

> Ex-Pfizer R&D chief LaMattina criticizes short-term pharma strategy. Item

Medical Device News

> C.R. Bard to pay $184M to end Davol suits. Story

> Synthes vet tapped as next Nobel Biocare chair. News

> MyoPowers closes $19M Series B round. Report

> Analyst: Infuse fallout could lead to Medtronic selling spine biz. Item

Drug Delivery News

> DNA cages can unleash meds inside cells. Article

> All eyes on pSivida for back-of-the-eye drug delivery. Report

> Europe OKs Merck Serono's prefilled IVF pen injector. Piece

And Finally... Outside of heart attacks, doctors are often too quick to use a $20,000 angioplasty to treat patients suffering from coronary artery disease, a new study suggests. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.